Free Trial
NYSE:AVNS

AVANOS MEDICAL Q3 2025 Earnings Report

AVANOS MEDICAL logo
$11.82 +0.50 (+4.37%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$11.80 -0.03 (-0.25%)
As of 10/3/2025 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AVANOS MEDICAL EPS Results

Actual EPS
N/A
Consensus EPS
$0.19
Beat/Miss
N/A
One Year Ago EPS
N/A

AVANOS MEDICAL Revenue Results

Actual Revenue
N/A
Expected Revenue
$164.50 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

AVANOS MEDICAL Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, October 29, 2025
Conference Call Time
9:00AM ET

Conference Call Resources

AVANOS MEDICAL Earnings Headlines

URGENT: The Market's 3 Red Flags Are Flashing
The warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed.tc pixel
See More AVANOS MEDICAL Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AVANOS MEDICAL? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AVANOS MEDICAL and other key companies, straight to your email.

About AVANOS MEDICAL

AVANOS MEDICAL (NYSE:AVNS) is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms. These solutions are intended to help reduce reliance on systemic opioids and support accelerated recovery protocols. The enteral feeding business provides a range of feeding tubes, pumps and accessories to deliver nutrition directly to the gastrointestinal tract, serving patients with swallowing disorders or nutritional deficiencies. In respiratory care, the company’s offerings include patient interfaces, breathing circuits and related disposables that aid in noninvasive ventilation, oxygen therapy and airway management.

Avanos Medical was established as a standalone company in January 2017 following a spin-off from Kimberly-Clark’s healthcare business. Headquartered in Alpharetta, Georgia, the company maintains a presence in key markets across North America, Europe, Asia Pacific and Latin America. Its global sales and distribution network supports hospitals, surgical centers and home healthcare providers with both direct sales teams and distributor partnerships.

Under the leadership of President and Chief Executive Officer Mike Coolbaugh, Avanos pursues a strategy centered on innovation, operational excellence and targeted acquisitions to expand its product portfolio and geographic reach. The company continues to invest in research and development to advance its current offerings and explore new technologies that address evolving clinical needs in pain management, nutritional support and respiratory therapy.

View AVANOS MEDICAL Profile

More Earnings Resources from MarketBeat